ASBP
Aspire Biopharma Holdings, Inc. (NASDAQ)
Healthcare — Biotechnology
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Price History
Fundamentals
| Market Cap | $6.92M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-7.09 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 38.76 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 44.4 |
| Beta | 0.16 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $35.00 |
| 52-Week Low | $0.11 |
| 50-Day Avg | $4.04 |
| 200-Day Avg | $5.38 |
| Avg Volume | $13.35M |
| Volume | 286.1K |
Performance Analysis
NEUTRALASBP presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report